A muulti-center study of the Efficacy in peritoneal Dialysis patients with renal anemia by initiating hypoxia-inducible factor prolyl hydroxylase (HIF-PH) Inhibitor, Roxadustat

A muulti-center study of the Efficacy in peritoneal Dialysis patients with renal anemia by initiating hypoxia-inducible factor prolyl hydroxylase (HIF-PH) Inhibitor, Roxadustat - Aichi Multi-center retrospective study: the efficacy in peritoneal dialysis patients with renal anemia by initiating hypoxia-inducible factor prolyl hydroxylase (HIF-PH) Inhibitor, Roxadustat (AMEDIST).

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046697

Enrollment

Registered

2022-01-31

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Who initiate Roxadustat anew or switching from EPO

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Therapeutic value of anemia after 24 weeks initiation Roxadustat	—

Secondary

Measure	Time frame
1) Iron metabolism (Fe, Ferritin, TIBC) 2) Adverse event (malignancy, retinopathy, age-related macular degeneration, exacerbation of BP, highperkalemia, deep vein thrombosis, ischemic heart disease, vascular calcification, pulmonary hypertension, heart failure)	—

Countries

Japan

Contacts

Public ContactShigehisa Koide

Fujita Health University Nephrology

skoide@fujita-hu.ac.jp0562-93-9245

Outcome results